TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03024216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab1200 mg IV
Description: Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab1200 mg IV
Description: Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
Study: NCT02700984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study: NCT01105637

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Augmented Exercise Program
Description: 12 week (3 x per week) exercise prescription
Study: NCT03494647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cheetah Heel Cup
Description: The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The X Brace
Description: The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
Study: NCT02475889

Intervention type: PROCEDURE
Intervention: Hepatic RFA
Description: Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.

Intervention type: PROCEDURE
Intervention: Primary tumor resection
Description: Primary tumor resection were performed pre- or post-RFA for liver metastases.

Intervention type: PROCEDURE
Intervention: Primary tumor resection
Description: Primary tumor resection were performed pre- or post-RFA for liver metastases.
Study: NCT02295722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1.5 g/m2 INFUSED

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 200 mg/m2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Day 0 - Stem cell infusion
Study: NCT00473876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo (Capsules)
Description: Similar dosing regime as active comparator
Study: NCT01099969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-styletted Endotrol endotracheal tube (ETT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-styletted Endotrol endotracheal tube (ETT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular endotracheal tube (ETT) with Gliderite stylet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular endotracheal tube (ETT) with Gliderite stylet
Study: NCT03135366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keheala

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
Study: NCT04083846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition
Study: NCT01138878

Intervention type: OTHER
Intervention: Focus Group Discussion
Description: FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
Study: NCT04083846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
Study: NCT01138878

Intervention type: OTHER
Intervention: Focus Group Discussion
Description: FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting

Intervention type: OTHER
Intervention: HIV test (serum or salivary)
Description: An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
Study: NCT04083846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
Study: NCT03189173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance
Description: An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral appliance plus oxygen
Description: Both treatments will be administered simultaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
Study: NCT04593134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise group
Description: exercise education: A 12-week regimen of homebased walking exercises, include moderate intensity for 40 min, three times a week.~We explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. Participants were instructed that the exercises would be effective only if they reached 40%-60% of the heart rate reserve, as determined by the Karvonen method, or 13-14 on the RPE.~Exercise education:~Weekly telephone or mobile application LINE consultations concerning exercise.we discussed whether participants' exercise fulfilled the prescribed intensity, duration, frequency and whether the participants experienced any adverse effects.
Study: NCT02648347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
Study: NCT01138878

Intervention type: OTHER
Intervention: Semi-structured telephone interview
Description: Telephone interview administered to patients offered an HIV test during the pilot period
Study: NCT03653871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performing Arts Instruction
Description: Professionally delivered performing arts curriculum
Study: NCT03320551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersion program
Description: Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
Study: NCT00949767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
Study: NCT00617305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match ambrisentan was administered orally once daily.
Study: NCT00949767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Matching volume) - Oral Solution, Oral, once 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Matching volume) - Oral Solution, Oral, once 14 days
Study: NCT01470677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachosil fibrin patch
Description: A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
Study: NCT03409874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interocclusal Appliance
Description: Interocclusal appliance worn every nights for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs
Description: diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Mobs
Description: Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
Study: NCT01455974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L
Description: After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
Study: NCT04597476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan
Description: Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo( Potato starch)
Description: Potato starch 4.4gram
Study: NCT00949767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Matching volume) - Oral Solution, Oral, once 14 days
Study: NCT02393209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Tablets
Study: NCT03716479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fiber
Description: 20 g of acacia gum will be added to orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fiber
Description: 40 g of acacia gum will be added to orange juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Control
Description: No acacia gum will be added to orange juice.
Study: NCT01973855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western Medicine
Description: Physical cooling,Hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM and Western Medicine
Description: Third Infectious diseases soup recipe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM and Western Medicine
Description: Third Infectious diseases soup recipe
Study: NCT00152633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Treatment with Losartan
Study: NCT00723957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2
Description: Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
Study: NCT00617305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
Study: NCT00949767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Matching volume) - Oral Solution, Oral, once 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Matching volume) - Oral Solution, Oral, once 14 days
Study: NCT00617305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
Study: NCT00723957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, 200 mg/m^2
Description: IV solutions, paclitaxel, 200 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (area under the concentration curve [AUC] 6)
Description: Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
Study: NCT00723957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (area under the concentration curve [AUC] 6)
Description: Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
Study: NCT01007526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCRT followed by VIDL chemotherapy
Description: CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
Study: NCT00746499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg raltegravir BID x 7 days
Study: NCT03543683

Intervention type: DRUG
Intervention: Osimertinib
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

Intervention type: DRUG
Intervention: Osimertinib
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
Study: NCT00974220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: single dose, 50 mcg of nebulized fentanyl citrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (placebo)
Description: single dose, 0.9% saline solution
Study: NCT01136343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle modified project
Description: education, counseling
Study: NCT01422005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Bimanual training
Description: Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy
Description: Conventional Occupational Therapy will be given to patients in the control group.